ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07737
0,03%
Bitcoin
60.819,83
-1,02%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. MannKind Corporation (MNKD)

  7. MannKind Corporation (MNKD) News

MNKD

MannKind (MNKD)

MannKind Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:MNKD
DatumZeitQuelleÜberschriftSymbolFirma
08/05/202422h18GlobeNewswire Inc.MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
08/05/202422h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNKDMannKind Corporation
08/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
06/05/202412h05GlobeNewswire Inc.MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
01/05/202422h00GlobeNewswire Inc.MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024NASDAQ:MNKDMannKind Corporation
30/04/202412h05GlobeNewswire Inc.MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesNASDAQ:MNKDMannKind Corporation
29/04/202412h05GlobeNewswire Inc.MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
03/04/202412h00GlobeNewswire Inc.MannKind Repays Certain Debt ObligationsNASDAQ:MNKDMannKind Corporation
26/03/202421h05GlobeNewswire Inc.MannKind Announces CFO TransitionNASDAQ:MNKDMannKind Corporation
11/03/202411h05GlobeNewswire Inc.INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsNASDAQ:MNKDMannKind Corporation
05/03/202412h05GlobeNewswire Inc.MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8NASDAQ:MNKDMannKind Corporation
04/03/202419h01GlobeNewswire Inc.MannKind Corporation Announces Participation at Upcoming ConferencesNASDAQ:MNKDMannKind Corporation
27/02/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
27/02/202422h00GlobeNewswire Inc.MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
20/02/202412h00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024NASDAQ:MNKDMannKind Corporation
15/02/202412h05GlobeNewswire Inc.MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®NASDAQ:MNKDMannKind Corporation
05/02/202412h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
05/02/202412h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
05/02/202412h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
05/02/202412h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
05/02/202412h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
05/02/202412h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
02/01/202412h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
02/01/202412h05GlobeNewswire Inc.MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 MillionNASDAQ:MNKDMannKind Corporation
28/12/202312h00GlobeNewswire Inc.MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
27/12/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
16/12/202303h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
15/12/202322h09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
15/12/202301h56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
14/12/202322h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
 Showing the most relevant articles for your search:NASDAQ:MNKD

Kürzlich von Ihnen besucht

TG
BAS
BASF
AMEX
SPY
SPDR S&P 500
TG
432
Arbor Metals
TG
ALV
Allianz
AMEX
XLV
Health Care Select Sector
NYSE
MCD
McDonalds
TG
LHA
Deutsche Lufthansa
FX
EURUSD
Euro vs US Dollar
DBI
MDAX
MDAX
TG
RHM
Rheinmetall
FX
EURGBP
Euro vs Sterling
NYSE
KO
Coca Cola
AMEX
XLE
Energy Select Sector SPDR
COIN
ETHUSD
Ethereum
DBI
DAX
DAX
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten